<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00668603</url>
  </required_header>
  <id_info>
    <org_study_id>U1030N1016</org_study_id>
    <secondary_id>HUS-231911</secondary_id>
    <nct_id>NCT00668603</nct_id>
  </id_info>
  <brief_title>Comparison of Vascular Findings Between Symptomatic and Asymptomatic Postmenopausal Women Before and During Hormone Therapy (HRT)</brief_title>
  <acronym>SYMPTOM</acronym>
  <official_title>Comparison of Vascular Findings Between Symptomatic and Asymptomatic Postmenopausal Women Before and During Hormone Therapy: A Randomized, Placebo-controlled Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PÃ¤ivikki and Sakari Sohlberg Foundation, Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emil Aaltonen Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Finnish Medical Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent large randomized, placebo-controlled studies assessing the health effects of HT
      question the overall benefits of long term HT, especially with respect to cardiovascular
      disease. However, recently menopausal women with severe hot flushes were mostly excluded from
      these trials. This was unfortunate since vasomotor symptoms may reflect different vascular
      sensitivity to estrogen or its deficiency, and therefore, the vascular responses to HT in
      women with and without hot flushes can differ.

      Aims of the present project are

        1. to compare vascular, cardiac and sympathetic function in recently menopausal women with
           or without severe vasomotor symptoms

        2. in a randomized placebo controlled clinical trial investigate vascular response to oral
           and trans-dermal HT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We recruit 160 healthy postmenopausal women between ages 48-55. Eighty women must have severe
      vasomotor symptoms (at least seven severe or moderate hot flush attacks per day) whereas 80
      comparators must be symptomless (no hot flushes). Thorough vascular function and risk factor
      assessments will be done, including clinical assessment of autonomic nervous system,
      endothelial function measurements, 24-hour ECG and blood pressure evaluation, and lipid and
      various other vascular surrogate marker measurements. In the first part of the study we
      compare these baseline measurements between women with or without severe vasomotor symptoms.
      In the second part of the study the women are randomized to receive placebo, oral estrogen,
      oral estrogen plus progestin or transdermal estrogen for 6 months. After the treatments the
      baseline assessments are repeated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vascular function</measure>
    <time_frame>0 and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac and sympathetic function</measure>
    <time_frame>0 and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Postmenopausal Vasomotor Symptoms</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Postmenopausal women with severe vasomotor symptoms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Postmenopausal women without vasomotor symptoms</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>17-b-estradiol</intervention_name>
    <description>2mg oral daily for 6 months</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>17-b-estradiol + medroxyprogeterone acetate</intervention_name>
    <description>2mg E2 + 5mg MPA daily for 6 months</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>1</arm_group_label>
    <other_name>Indivina</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>17-b-estradiol hemihydrate</intervention_name>
    <description>1 mg skin gel daily for 6 months</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>1</arm_group_label>
    <other_name>Divigel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo pill + gel</intervention_name>
    <description>placebo daily for 6 months</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women between ages 48-55

          -  Minimum of 6 months and maximum of 36 months from last menstrual period

          -  Postmenopausal status of these women will be confirmed by level of FSH that should
             exceed 30 U/l

          -  Eighty women must have severe vasomotor symptoms (at least seven severe or moderate
             hot flush attacks per day) whereas eighty comparators must be symptomless

        Exclusion Criteria:

          -  smoking

          -  hysterectomy

          -  dyslipidemia

          -  overt hypertension (blood pressure &gt; 140/90)

          -  diabetes

          -  any regular medication

          -  HT in the previous 3 months

          -  body mass index over 27
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>48 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomi S Mikkola, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Hospital, Department of Obstetrics and Gynecology</name>
      <address>
        <city>Helsinki</city>
        <zip>00029 HUS</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <reference>
    <citation>Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res. 2002 Feb 15;53(3):605-19. Review.</citation>
    <PMID>11861031</PMID>
  </reference>
  <reference>
    <citation>Mikkola TS, Clarkson TB. Coronary heart disease and postmenopausal hormone therapy: conundrum explained by timing? J Womens Health (Larchmt). 2006 Jan-Feb;15(1):51-3.</citation>
    <PMID>16417418</PMID>
  </reference>
  <reference>
    <citation>Collins P, Rosano G, Casey C, Daly C, Gambacciani M, Hadji P, Kaaja R, Mikkola T, Palacios S, Preston R, Simon T, Stevenson J, Stramba-Badiale M. Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists. Eur Heart J. 2007 Aug;28(16):2028-40. Epub 2007 Jul 20.</citation>
    <PMID>17644507</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2008</study_first_submitted>
  <study_first_submitted_qc>April 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2008</study_first_posted>
  <last_update_submitted>February 18, 2016</last_update_submitted>
  <last_update_submitted_qc>February 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University</investigator_affiliation>
    <investigator_full_name>Tomi S. Mikkola</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Postmenopausal vasomotor symptoms</keyword>
  <keyword>Hot flush</keyword>
  <keyword>Vascular function</keyword>
  <keyword>Cardiac function</keyword>
  <keyword>Cardiovascular risk factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

